S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.82 CNY -1.39% Market Closed
Market Cap: 35.5B CNY
Have any thoughts about
Shenzhen Salubris Pharmaceuticals Co Ltd?
Write Note
Shenzhen Salubris Pharmaceuticals Co Ltd
/
Cash Flow Statement
/
Cash Paid for Dividends

Shenzhen Salubris Pharmaceuticals Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Salubris Pharmaceuticals Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Cash Paid for Dividends
-¥546m
CAGR 3-Years
-248%
CAGR 5-Years
9%
CAGR 10-Years
-3%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash Paid for Dividends
-¥652.1m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash Paid for Dividends
-¥2.2B
CAGR 3-Years
-56%
CAGR 5-Years
-41%
CAGR 10-Years
-27%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash Paid for Dividends
-¥1.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-26%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash Paid for Dividends
-¥3.8B
CAGR 3-Years
9%
CAGR 5-Years
-20%
CAGR 10-Years
-26%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash Paid for Dividends
-¥18.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Salubris Pharmaceuticals Co Ltd
Glance View

Market Cap
34.7B CNY
Industry
Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. stands as a dynamic player in the pharmaceutical landscape, tracing its origins to China’s bustling hub of innovation, Shenzhen. From its inception, Salubris has steadily cultivated a robust portfolio, deeply rooted in the development, production, and commercialization of a wide array of pharmaceutical products. With a steadfast focus on cardiovascular and cerebrovascular medications, the company has adeptly positioned itself to meet significant medical needs, leveraging its expertise to produce both traditional and novel therapies. This focus is complemented by an ambitious expansion into biopharmaceuticals, a sector that holds significant potential for growth. Salubris thrives by combining its innovative R&D capabilities with efficient production processes, ensuring that its offerings not only reach a broad customer base but also adhere to stringent quality standards. The company’s business model revolves around a meticulously crafted combination of research innovation and strategic partnerships. By investing significantly in research and development, Salubris ensures a pipeline filled with promising drugs poised to address prevalent health issues. The company maximizes its revenues through its sales network, which extends beyond domestic borders, tapping into international markets where demand for high-quality pharmaceuticals continues to rise. Additionally, Salubris has been proactive in pursuing collaborations and partnerships, both to bolster its research capabilities and to navigate regulatory landscapes more effectively. By marrying these strategic approaches, Salubris not only sustains its competitive edge but also ensures a steady growth trajectory, embodying a business narrative that resonates with resilience and forward-thinking ambition.

Intrinsic Value
25.4 CNY
Overvaluation 20%
Intrinsic Value
Price
S
What is Intrinsic Value?

See Also

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-546m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Salubris Pharmaceuticals Co Ltd's Cash Paid for Dividends amounts to -546m CNY.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-3%

Over the last year, the Cash Paid for Dividends growth was 1%. The average annual Cash Paid for Dividends growth rates for Shenzhen Salubris Pharmaceuticals Co Ltd have been -248% over the past three years , 9% over the past five years , and -3% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.